Reshma Kewalramani bought $3.9M of Vertex Pharmaceuticals Incorporated (VRTX)

Executed Aug 6 2025, disclosed Aug 7 2025, 1 day later.

Value, as filed

$3.9M

10,000 sh across 2 lots

Executed

Aug 6 2025

the trade date, as filed

Disclosed

Aug 7 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+2.9%

+5.6% from execution

Over the 21 trading sessions from the disclosed entry session (Aug 7 2025), the stock returned +2.9% (delay-adjusted); from the execution session (Aug 6 2025), +5.6%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

RK Reshma Kewalramani CEO & President profile →

Reshma Kewalramani (CEO & President) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $19.7M of VRTX (39,880 sh across 12 lots, as filed), executed Feb 27.

The name

VRTX Vertex Pharmaceuticals Incorporated VRTX · Healthcare · 90 filings in 24 months ticker →

Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Reshma Kewalramani in VRTX

VRTXSALE Vertex Pharmaceuticals Incorporated $19.7M
39,880 sh across 12 lots
Exec Feb 27
Filed Mar 3 · 5:30 PM ET VRTXSALE Vertex Pharmaceuticals Incorporated $7.8M
15,198 sh × $515.00
Exec Nov 8 2024
Filed Nov 12 2024 · 5:30 PM ET